Critique Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Sign: In combination with chemotherapy, for the remedy of Grownup people with locally recurrent unresectable or metastatic triple-adverse breast most cancers which have not obtained prior chemotherapy for metastatic sickness and whose tumours express programmed cell Demise-ligan